Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191 [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184]
Corresponding Author of This Article
Giovan Giuseppe Di Costanzo, Department of Transplantation, Liver Unit, Cardarelli Hospital, Via A Cardarelli 9, 80131, Naples, Italy. ggdicostanzo@libero.it
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. May 28, 2015; 7(9): 1184-1191 Published online May 28, 2015. doi: 10.4254/wjh.v7.i9.1184
Intermediate hepatocellular carcinoma: How to choose the best treatment modality?
Giovan Giuseppe Di Costanzo, Raffaella Tortora
Giovan Giuseppe Di Costanzo, Raffaella Tortora, Department of Transplantion, Liver Unit, Cardarelli Hospital, 80131 Napoli, Italy
Author contributions: Both authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; both authors also contributed to drafting the article, revising it critically for important intellectual content and final approval of the version to be published.
Conflict-of-interest: The authors have declared no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Giovan Giuseppe Di Costanzo, Department of Transplantation, Liver Unit, Cardarelli Hospital, Via A Cardarelli 9, 80131, Naples, Italy. ggdicostanzo@libero.it
Fix: +39-081-7472208
Received: September 5, 2014 Peer-review started: September 6, 2014 First decision: September 28, 2014 Revised: January 18, 2015 Accepted: February 9, 2015 Article in press: February 11, 2015 Published online: May 28, 2015 Processing time: 257 Days and 1.8 Hours
Core Tip
Core tip: Intermediate stage, or stage B according to Barcelona Clinic Liver Cancer classification, of hepatocellular carcinoma (HCC) comprises a heterogeneous population with different tumor burden and liver function. This heterogeneity is confirmed by the large variability in treatment and survival, the choice of the best treatment in the patient with intermediate stage HCC is a difficult task. A multisciplinary evaluation of each intermediate stage HCC patient is recommended for planning the best therapeutic strategy and this review was aimed to discuss about the existing evidences regarding this topic. Due to the heterogeneity of intermediate HCC, the use of different therapies (combination treatment) is likely the best choice in most of the cases offering the opportunity of a treatment tailored to the single patient.
